Tot Biopharm Co. Ltd., of Suzhou, China, said it completed a series B financing round, raising $102 million. The company focuses on the R&D, manufacturing and marketing of antitumor drugs and has more than 10 drugs at the research stage, including three biologics and three small molecules, which have received IND approvals, as well as one antibody-drug conjugate, which is expected to receive approval in the near future.